Elevate Easter Celebrations: Nework Introduces MoveMate Series Portable TVs for Effortless Family Moments

POMONA, Calif., April 4, 2026 /PRNewswire/ -- As families prepare for Easter, a season defined by family reunions, outdoor festivities, and shared traditions, Nework, an audiovisual and collaborative solutions provider for education, business, and home, is redefining seasonal entertainment with its MoveMate Series Portable TVs. Designed for ultimate mobility and premium performance, the MoveMate lineup offers a sophisticated way to bring digital entertainment into every corner of the holiday celebration. To celebrate the season, Nework has launched its Spring Sale, featuring an instant $60 discount across the series. The MoveMate AI is now available for $599.99, while the MoveMate Hi-Fi flagship is priced at $689.99.

Redefining Holiday Entertainment

The Nework MoveMate Hi‑Fi exemplifies how technology can enrich Easter gatherings with minimal effort. During backyard brunches or patio parties, the device functions as a mobile backdrop, effortlessly rolling from the kitchen to the lawn on its silent casters. Its professionally tuned 44W audio system, complete with quad speakers and a dedicated subwoofer, fills open spaces with warm, room‑enveloping sound, making it ideal for holiday playlists, family movies, or ambient visuals that add charm to spring celebrations. The 27‑inch FHD display provides crisp imagery at any angle, while the rotatable and height‑adjustable design ensures clear views whether placed beside a picnic table or within a cozy indoor corner.

As spring evenings warm up, outdoor movie nights have become a beloved seasonal ritual. After an afternoon of egg hunts, the MoveMate Hi‑Fi can be wheeled onto the grass to create an instant open‑air cinema. Its powerful audio performance strengthens the sense of immersion, while Bluetooth, Wi‑Fi 6, and streaming app compatibility ensure quick and smooth setup. For families who enjoy capturing shared memories on camera, the device's HD camera adds a layer of convenience and security with a physical privacy cover.

A Modern Gift for the Modern Home

For families seeking a standout Easter surprise, the MoveMate Hi‑Fi also lends itself to creative gifting. Instead of filling oversized baskets with candy or toys, households are presenting the portable TV as the "grand prize" of Easter morning. As a premium yet practical gift, it brings long‑term entertainment value through its smart system, which offers access to streaming platforms, cooking apps, video‑call tools, and more. The built‑in battery delivers up to eight hours of wireless use, supporting the spontaneity of holiday activities.

The Nework MoveMate AI presents another compelling option for family use and Easter gifting. With a 27‑inch multi‑touch display, up to 16 hours of battery life, and EDLA‑certified Android 14 smart features, the MoveMate AI offers versatility for both entertainment and productivity. It functions as a cooking companion during Easter meal preparations, streaming step‑by‑step recipes or hosting video chats with distant relatives. Its adjustable stand and five‑wheel mobility make repositioning effortless in busy kitchens or living rooms, while the Qualcomm octa‑core processor ensures smooth performance across apps, from YouTube tutorials to streaming platforms.

This renewed focus on adaptive home technology aligns with Nework's vision. "At Nework, technology should adapt to people's lives, not the other way around. The MoveMate series is designed to bring flexibility, connection, and joy to everyday moments, especially during meaningful occasions like Easter," said the CEO of Nework.

As families across the United States embrace more flexible, mobile, and immersive entertainment experiences, the MoveMate Series continues to stand out as a forward‑thinking lifestyle upgrade. Whether used indoors for cooking, outdoors for movie nights, or as a creative Easter morning reveal, it offers a premium blend of functionality and festive delight.

For more information, please visit https://nework.us/, or connect with Nework:

Facebook: https://www.facebook.com/neworkus

LinkedIn: https://www.linkedin.com/company/nework-us/

X: https://x.com/Nework_us 

Instagram: https://www.instagram.com/nework.us

YouTube: https://www.youtube.com/@Nework-us 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Elevate Easter Celebrations: Nework Introduces MoveMate Series Portable TVs for Effortless Family Moments

HANGZHOU, China, April 3, 2026 /PRNewswire/ -- A team led by principal investigators Bobo Dang and Ting Zhou at Westlake University/Westlake Laboratory reported in Science a high-throughput platform for engineering fast-acting covalent protein therapeutics. Their work, titled "A high-throughput selection system for fast-acting covalent protein drugs," opens new avenues for next-generation biologics.

Covalent small-molecule drugs have shown great success in cancer therapy by forming irreversible bonds with their targets. This has inspired efforts to extend covalent strategies to protein therapeutics, especially engineered miniproteins. However, their development is limited by a kinetic mismatch: Miniproteins are rapidly cleared in vivo, whereas covalent bond formation is typically slow. In addition, high-throughput platforms for systematically optimizing covalent protein reactivity have been lacking.

To address this challenge, the researchers proposed that precise spatial positioning of chemical warheads within protein scaffolds could enable molecular preorganization, thereby accelerating covalent bond formation without increasing intrinsic reactivity (Fig. 1).

Based on this concept, the team developed a high-throughput platform that combines yeast surface display with chemoselective protein modification to screen diverse crosslinkers and millions of protein variants. By optimizing warhead placement and the local chemical environment, the platform enables rapid and irreversible target engagement.

Using this platform, the researchers developed a covalent antagonist targeting PD-L1, termed IB101. Structural analysis revealed that IB101 forms a defined binding pocket that precisely positions the warhead in a reactive conformation, greatly accelerating covalent bond formation. Functionally, IB101 effectively blocks the PD-1/PD-L1 immune checkpoint pathway and demonstrates strong antitumor activity in mouse models. Notably, despite its short in vivo half-life, IB101 achieves durable target engagement and tumor suppression, outperforming conventional antibody-based therapies under comparable conditions.

The platform was further applied to cytokine engineering, leading to the development of a covalent IL-18 variant, IB201. This engineered cytokine rapidly forms a covalent interaction with its receptor, enhancing signaling strength and duration. In vivo studies showed that IB201 induces potent antitumor immune responses without detectable systemic toxicity. These results highlight the potential of covalent engineering to improve the efficacy and safety of cytokine-based therapies.

Beyond immunotherapy targets, the platform was also applied to develop a covalent inhibitor targeting the receptor-binding domain (RBD) of SARS-CoV-2. This molecule achieves durable viral neutralization, demonstrating the versatility of the approach across different therapeutic modalities.

This study establishes a general strategy for engineering fast-acting covalent protein therapeutics. By enabling covalent bond formation on timescales compatible with rapid in vivo clearance, the platform overcomes a fundamental limitation in the field.

These findings provide a new framework for designing biologics with both rapid kinetics and sustained target engagement, with broad implications for cancer immunotherapy, antiviral therapy, and beyond.

Media Contact: 

Chi Zhang
media@westlake.edu.cn 
+86-15659837873

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Fast-Acting Covalent Protein Drugs From a New High-Throughput Platform